Mark A. Frye, MD

Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania

January 6, 2015

Mark A. Frye, Scott Crow, Susan L. McElroy, et al

Article

Illness Progression as a Function of Independent and Accumulating Poor Prognosis Factors in Outpatients With Bipolar Disorder in the United States

December 18, 2014

Many patients with bipolar disorder in the United States experience a deteriorating course of illness despite naturalistic treatment in the community. In this study, Post and colleagues explored this...

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

Original Research

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

July 22, 2014

Joseph R. Calabrese, Terence A. Ketter, Ronghua Yang, et al

Original Research

Supraphysiologic Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Study

November 26, 2013

Mark A. Frye, Georg Juckel, Michael Bauer, et al

Commentary

Paradigm Shift: Preliminary Clinical Categorization of Ultrahigh Risk for Childhood Bipolar Disorder to Facilitate Studies on Prevention

February 15, 2013

Kiki Chang, Mark A. Frye, Robert M. Post

Original Research

Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients

March 20, 2012

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

Article

International Consensus Group on Depression Prevention in Bipolar Disorder

October 24, 2011

Mark A. Frye, Susan L. McElroy, Eduard Vieta, et al

Original Research

Complexity of Pharmacologic Treatment Required for Sustained Improvement in Outpatients With Bipolar Disorder

September 15, 2010

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

Original Research

Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

July 27, 2010

Joseph R. Calabrese, Terence A. Ketter, James M. Youakim, et al

Original Research

Early-Onset Bipolar Age & Treatment Delay

July 15, 2010

Read an article examining the influence of age at early onset bipolar disorder and the delay in time to first treatment on morbidity in adulthood.

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

Original Research

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

October 15, 2009

Mark A. Frye, Mauricio Tohen, Franco Benazzi, et al

Original Research

Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo

August 11, 2009

Joseph R. Calabrese, Terence A. Ketter, Mark A. Frye, et al

Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania

Illness Progression as a Function of Independent and Accumulating Poor Prognosis Factors in Outpatients With Bipolar Disorder in the United States

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Supraphysiologic Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Paradigm Shift: Preliminary Clinical Categorization of Ultrahigh Risk for Childhood Bipolar Disorder to Facilitate Studies on Prevention

Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients

International Consensus Group on Depression Prevention in Bipolar Disorder

Complexity of Pharmacologic Treatment Required for Sustained Improvement in Outpatients With Bipolar Disorder

Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

Early-Onset Bipolar Age & Treatment Delay

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo

ELSEWHERE:

FOLLOW US:

Mark A. Frye, MD

Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania

Illness Progression as a Function of Independent and Accumulating Poor Prognosis Factors in Outpatients With Bipolar Disorder in the United States

Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Supraphysiologic Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Paradigm Shift: Preliminary Clinical Categorization of Ultrahigh Risk for Childhood Bipolar Disorder to Facilitate Studies on Prevention

Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients

International Consensus Group on Depression Prevention in Bipolar Disorder

Complexity of Pharmacologic Treatment Required for Sustained Improvement in Outpatients With Bipolar Disorder

Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

Early-Onset Bipolar Age & Treatment Delay

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo

Learn More About Psychedelics in Psychiatry

Subscribe to readmore articles

Subscribe to read
more articles